Method of predicting the clinical response to cisplatin or carboplatin chemotherapeutic treatment

摘要

The present invention relates to a method for classifying non-small-cell lung cancer (NSCLC) patients, for selecting an effective chemotherapy and for predicting survival of those NSCLC patients, based on the determination of the trnetlxylation level of the 14-3-3 sigma gene. The methylation status of the 34-3-3 sigma gene can be easily determined in a serum sample.